Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital.
E Van den EyndeOriol GaschJ C OlivaE PrietoS CalzadoA GomilaM L MachadoL FalguerasS OrtonobesA MorónS CapillaG NavarroJ OristrellM CervantesM NavarroPublished in: Infectious diseases (London, England) (2021)
Combined treatment with corticosteroids and tocilizumab reduced mortality with about 25% in patients with severe COVID-19 pneumonia. Corticosteroids alone also resulted in lower in-hospital mortality rate compared to patients receiving only antiviral and antibiotic treatment. Corticosteroids alone or combined with tocilizumab may be considered in patients with severe COVID-19 pneumonia.
Keyphrases
- coronavirus disease
- sars cov
- rheumatoid arthritis
- early onset
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- healthcare
- type diabetes
- respiratory syndrome coronavirus
- systemic lupus erythematosus
- cardiovascular disease
- intensive care unit
- disease activity
- community acquired pneumonia
- combination therapy
- replacement therapy
- coronary artery disease